GSK Collaborates with Vir to Develop Treatment for COVID-19
Shots:
- GSK to invest in Vir with $250M at $37.73- a 10% premium to the closing share price on Friday- March 27- 2020 and enters into an agreement to develop a potential Ab treatment against COVID-19
- The alliance will leverage Vir’s mAb platform to identify Ab that can be used as preventive option addressing COVID-1 and utilize GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and AI to identify anti-coronavirus compounds targeting the cellular host genes
- Initially- the companies will accelerate Vir’s Ab- VIR-7831 and VIR-7832 that demonstrates high affinity in neutralizing SARS-CoV-2 and is expected to be accelerated into P-II studies within the next 3-5mos.
Click here to read full press release/ article
Ref: GSK | Image: GSK
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com